Enzymatic Release
Studying the detailed structural and functional characterization of different types of glycans is essential to understand the mechanism of various biological activities and the pathology of several diseases. CD BioGlyco has been trying to develop simple and effective enzymatic methods to release glycans from complex biological samples. We expect to be your research assistant in the field of glycobiology.
Unlock Glycans: Enzymatic Release for Deeper Insights

Glycosylation is an important way of post-translational modification of proteins, which has a variety of biological functions, such as immune recognition, signal transduction, cell adhesion, and tumorigenesis. Therefore, the development of effective methods to release glycans from the protein backbone is of great significance to the study of their structure and function.
In contrast to chemical methods of glycan release, enzymatic release can be carried out with minimum instructions in any laboratory. In the past two decades, more and more enzymes including endoglycosidases and glycosidases have been reported to release glycans from glycoproteins under mild conditions. The endoglycosidase endo-β-N-acetylglucosaminidase H (Endo H), peptide-N4-(acetyl-β-glucosaminyl) asparagine amidase F (PNGase F), and PNGase A are the most preferred endoglycosidases, N-glycans can be conveniently and non-selectively released from glycoproteins using these enzymes.
Key Technologies
At CD BioGlyco, our glycan enzymatic release services are underpinned by a robust suite of core technologies designed for unparalleled specificity and efficiency. Our expertise lies in the strategic application of a comprehensive panel of highly purified glycosidases and glycoamidases. This includes industry-standard enzymes like PNGase F for the complete and gentle removal of N-linked glycans, as well as an extensive range of exoglycosidases and endoglycosidases optimized for specific glycan linkages and structures. We leverage proprietary enzymatic blends and optimized reaction conditions that are tailored to the unique characteristics of each sample, ensuring maximum glycan release yield with minimal degradation or structural alteration. Our advanced enzymatic platforms are complemented by state-of-the-art analytical instrumentation, allowing for precise monitoring of the release process and immediate preparation for subsequent analytical workflows.
Comprehensive Glycan Release: Tailored Solutions for Every Glycosylation Need
Enzymes are useful for the structural analysis of glycans and polysaccharides and for establishing structure-activity relationships in biological systems. To better characterize glycans on proteins, CD BioGlyco has developed an advanced glycan enzymatic release platform. We provide efficient and accurate release services of N-glycan, fucose, galactose, N-acetylgalactosamine (GalNAc), O-glycosylated protein, core-1 O-glycan, and sialic acid for our clients.
Workflow
Publication Data
Journal: Molecules
IF: 4.6
Published: 2023
Results: The authors emphasize the intricacies of protein N-glycosylation and its impact on glycoprotein structure and function, noting that the natural heterogeneity of N-glycans often obscures their precise biological roles. To overcome this, the research details efforts in glycoprotein in vitro N-glycan engineering, specifically through the use of purified recombinant glycoside hydrolases expressed in E. coli. This approach is designed to generate glycoproteins with homogeneous N-glycoforms, thereby enabling clearer elucidation of specific N-glycan functions and facilitating the development of enhanced glycoprotein therapeutics.
Fig.1 Glycoprotein in vitro N-glycan processing from high-mannose to disialylated biantennary complex-type N-glycans. (Zhang, et al., 2023)
Applications
- Biopharmaceutical development and quality control: In the biopharmaceutical industry, glycosylation significantly impacts the efficacy, immunogenicity, and stability of therapeutic proteins (e.g., antibodies, enzymes). Enzymatic glycan release is crucial for detailed characterization of glycosylation patterns, enabling comparability studies, biosimilar development, and routine quality control to ensure product safety and potency.
- Biomarker discovery: Altered glycosylation is a hallmark of numerous diseases, including cancer, inflammatory conditions, and infectious diseases. By enabling precise glycan profiling, enzymatic release facilitates the discovery of novel glycan biomarkers for early disease detection.
- Vaccine development: Glycans on pathogens often serve as key targets for immune recognition. Understanding the glycosylation of vaccine antigens through enzymatic release and subsequent analysis is vital for designing more effective vaccines that elicit robust and targeted immune responses.
- Fundamental glycobiology research: Enzymatic glycan release is a foundational technique for elucidating the roles of glycans in various biological processes, including cell signaling, cell adhesion, development, and immunity. It allows for the precise investigation of glycan structure-function relationships.
Advantages
- Exceptional gentleness: Our enzymatic methods are mild, which minimizes the risk of glycan degradation or structural rearrangements, ensuring that the released glycans accurately reflect their native state.
- High yield and reproducibility: Through optimized enzyme selection and reaction conditions, we consistently achieve high yields of released glycans. Our standardized protocols and rigorous quality control measures guarantee excellent reproducibility, providing reliable data for your most critical experiments.
- Compatibility with downstream analysis: Glycans released using our enzymatic methods are perfectly suited for a wide array of downstream analytical techniques, including advanced mass spectrometry (MS), high-performance liquid chromatography (HPLC), hydrophilic interaction liquid chromatography (HILIC), and capillary electrophoresis (CE). The purity and intactness of the released glycans ensure optimal performance in these high-resolution analyses.
- Customizable solutions: CD BioGlyco offers flexible and customizable enzymatic release strategies tailored to your specific sample type, research goals, and target glycan structures. Our expert team works closely with you to design the most effective workflow.
Frequently Asked Questions
CD BioGlyco focuses on teamwork and uses first-class experimental platforms to provide global biotechnology companies and scientific research institutions with efficient and high-quality services related to glycobiology. Our fast and effective solutions will greatly accelerate the progress of our clients' projects. Please contact us directly for more detailed information if you need scientific assistance.
Associated Services
Beyond our premier glycan enzymatic release services, CD BioGlyco offers a suite of complementary services designed to provide a complete solution for your glycoscience research needs. These offerings are seamlessly integrated with your glycan release projects to achieve your comprehensive analytical goals.
Reference
- Zhang, L.; et al. Glycoprotein in vitro N-glycan processing using enzymes expressed in E. coli. Molecules. 2023, 28(6): 2753. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform














